To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Titrated THC:CBD Improves Pain and Spasticity Compared to Placebo Over 12 Weeks for Resistant MS

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
March 2019

Titrated THC:CBD Improves Pain and Spasticity Compared to Placebo Over 12 Weeks for Resistant MS

Vol: 8| Issue: 3| Number:10| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Sativex as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial

Int J Neurosci. 2018 Sep 13:1-10.

Contributing Authors:
M Marinelli C Vila JE Markova B Akmaz C Trompke A Lentschat U Essner

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

106 patients with resistant multiple sclerosis who had demonstrated adequate treatment response to Sativex (tetrahydrocannabinol and cannabidiol oromucosal spray) treatment in a 4-week trial phase were randomized to Sativex or placebo for 12 weeks after 1-4 week washout from the trial phase. The purpose of the study was to determine if tetrahydrocannabinol and cannabidiol oromucosal spray (THC:CBD...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.

Continue